Economy/Home · Economy

Inventera Submits U.S. FDA Phase 1 IND Application for MRCP-Specific Oral Contrast Agent 'INV-003 Liquid'

Inventera announced on the 17th that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial of 'INV-003 Liquid,' an oral contrast agent specialized for magnetic resonance cholangiopancreatography (MRCP). The applicat

Oseong Kwon
Staff Reporter
4 min read
Inventera Submits U.S. FDA Phase 1 IND Application for MRCP-Specific Oral Contrast Agent 'INV-003 Liquid'
CBC News

Inventera announced on the 17th that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial of 'INV-003 Liquid,' an oral contrast agent specialized for magnetic resonance cholangiopancreatography (MRCP). The application was filed on the 17th Korea time, which was the 16th U.S. time.

[Trial Design] This Phase 1 clinical trial is an open-label, single-center, single-dose, dose-escalation study aimed at evaluating the safety, tolerability, and efficacy of the oral MRCP contrast agent INV-003 Liquid in clinically stable adults who require MRCP for follow-up observation or differential diagnosis. The target diseases are biliary and pancreatic conditions requiring MRCP, and the trial will be conducted at a single institution in the United States.

[Scale and Schedule] The target number of subjects is up to 30, and the clinical trial period is approximately 12 months from the start of the study (IND approval). The trial will evaluate the safety and tolerability of the investigational drug to determine the maximum tolerated dose (MTD) and decide the recommended Phase 2 dose (RP2D). After a single oral administration of the investigational drug to adult subjects, safety and tolerability, including dose-limiting toxicity (DLT), will be evaluated, along with an efficacy assessment of MRCP images.

[Investor Cautions] The company stated that the trial design, number of subjects, and trial institution may change depending on progress. It also disclosed through investor cautions that the statistical probability of a clinical trial drug receiving final approval as a medicine is known to be around 10%, and that if results during the clinical trial or product approval process fall short of expectations, the company may change or abandon its commercialization plans.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.